Member Info for flava

🟢 Patent Allowance: The US Patent Office has granted a new patent surrounding the biomarkers sTNFR1 and sTNFR2, which are core components of Renalytix's KidneyIntelX.dkd test.

🟢 KidneyIntelX.dkd Background: This is an artificial intelligence-driven blood test that assesses the risk of declining kidney function in patients with type 2 diabetes and early-stage chronic kidney disease. It was authorized by the FDA in June 2023.

Why This Matters

🟢 Strengthens Intellectual Property: The patent reinforces Renalytix's ownership of the core technology behind its KidneyIntelX test.

🟢 Competitive Advantage: The patent, along with other factors like FDA authorization and insurance coverage, positions Renalytix strongly in the market for kidney disease management.

🟢 Barriers to Entry: The strong intellectual property position could make it more difficult for competitors to enter the market with similar solutions.

🟢 Focus on Innovation: The announcement emphasizes Renalytix's commitment to research and development in the field of kidney disease diagnosis.

🟢 European Expansion: Renalytix is pursuing a similar intellectual property strategy in Europe, aiming to expand the reach of KidneyIntelX.

In short, this patent allowance is a significant development for Renalytix, adding protection to its technology and potentially improving its market position.

Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA authorized artificial intelligence (AI) enabled blood test to assess risk of progressive kidney function decline for individuals with type 2 diabetes and early-stage chronic kidney disease, announces that the US Patent Office has issued a new notice of allowance of claims surrounding the biomarkers sTNFR1 and sTNFR2 used in the kidneyintelX.dkd test. These claims were filed under US Patent Application No. 16/671.256 by the Joslin Diabetes Center and this patent is exclusively licensed to Renalytix. KidneyintelX.dkd received Food and Drug Administration de Novo marketing authorization on June 29, 2023.

The newly allowed claims further strengthen the core intellectual property underpinning the KidneyIntelX technology by directly incorporating sTNFR1 and sTNFR2 into a set of consolidated claims directed towards identifying risk of early kidney function decline, thereby enabling therapeutic strategies for those at increased risk of progressive decline.

The Company believes this development reflects the Renalytix strategy of innovation in biomarker research, development and translation in collaboration with the Joslin Diabetes Center and other leading research partners globally. When taken together with other key milestones, such as FDA De Novo marketing authorization, broad insurance coverage and published clinical utility and outcomes data, Renalytix believes this increases its competitive advantage. The Company also believes this creates further barriers to entry in the large addressable market for optimizing clinical management of kidney disease to drive improved patient outcomes. A similar strategy to protect Renalytix’s intellectual property is being pursued in Europe, which also presents a large opportunity for KidneyIntelX expansion.

Good morning, everyone! Let's have a fantastic day today.

Focus on the reasons we're investing here and ignore negativity.

You have to be in it to win it!

Shorts on fire soon.

US market is opening in 20min and we don't need running commentary. Thanks

They all small app trades worth few $$ :)

Why this matters:

The conference provides Renalytix with an opportunity to connect with potential investors and raise awareness about their work in kidney health diagnostics.

This type of exposure can be important for companies in the medical technology and diagnostics field.

Management will be participating in one-on-one meetings with investors 🔥🔥

Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic

Tools Conference

LONDON and SALT LAKE CITY, February 9, 2024 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will take place February 13-14, 2024 in Snowbird, Utah. Given the format of this event, no formal company presentation is expected. Management will be participating in one-on-one meetings with investors during the event and meetings can be requested through BTIG.

Keep loading up and sell over 100p soon.

Mozax - 90 pence from the chairman is making a statement. This is undervalued and ready to pop.

Sentiment and momentum will dictate SP movements. If you look at yesterday's price action, you'll see that no one on the LSE board posted anything up until in the afternoon. There was a 60% rise in the morning and then a 220% increase at close in the UK.

The US market will react to UK SP action this afternoon.

Let's wait and see.

I just manage to top-up more, silly drop and profit taking. nothing has changed.

Pi's paid 75p couple of hours ago. Just check out the 32k buy at 71p

Kids needs to learn that US Market open at 14:30 UK time.

Someone paid 70.30p for 32k worth of shares.

08:54:54 70.30 45,000 31.64k

Just relax and let it go slowly.

It's an MM's game; panic sellers will lose out, while those with nerves of steel will win the game.

Lol what a sily old man. Keep talking to yourself mental case.

We need wake up the Yanks this afternoon.

I'm predicting it's going to increase to 250% today.